MX2020005423A - Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. - Google Patents
Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.Info
- Publication number
- MX2020005423A MX2020005423A MX2020005423A MX2020005423A MX2020005423A MX 2020005423 A MX2020005423 A MX 2020005423A MX 2020005423 A MX2020005423 A MX 2020005423A MX 2020005423 A MX2020005423 A MX 2020005423A MX 2020005423 A MX2020005423 A MX 2020005423A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- new compounds
- cartilage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720101.3A GB201720101D0 (en) | 2017-12-02 | 2017-12-02 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| GBGB1817343.5A GB201817343D0 (en) | 2018-10-25 | 2018-10-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| PCT/EP2018/082537 WO2019105886A1 (en) | 2017-12-02 | 2018-11-26 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005423A true MX2020005423A (es) | 2020-08-27 |
Family
ID=64564856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005423A MX2020005423A (es) | 2017-12-02 | 2018-11-26 | Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11339166B2 (https=) |
| EP (1) | EP3717471B1 (https=) |
| JP (1) | JP7326276B2 (https=) |
| KR (1) | KR102720958B1 (https=) |
| CN (1) | CN111433200B (https=) |
| AU (1) | AU2018374456B2 (https=) |
| BR (1) | BR112020010364A2 (https=) |
| CA (1) | CA3084090A1 (https=) |
| CO (1) | CO2020008066A2 (https=) |
| CY (1) | CY1125044T1 (https=) |
| DK (1) | DK3717471T3 (https=) |
| ES (1) | ES2908283T3 (https=) |
| HU (1) | HUE057581T2 (https=) |
| IL (1) | IL274938B2 (https=) |
| MA (1) | MA51200A (https=) |
| MX (1) | MX2020005423A (https=) |
| MY (1) | MY201849A (https=) |
| PH (1) | PH12020550725B1 (https=) |
| PL (1) | PL3717471T3 (https=) |
| PT (1) | PT3717471T (https=) |
| SG (1) | SG11202004925QA (https=) |
| TW (1) | TW201930301A (https=) |
| WO (1) | WO2019105886A1 (https=) |
| ZA (1) | ZA202004025B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| SG11202004925QA (en) * | 2017-12-02 | 2020-06-29 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| GB201907558D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| GB201907616D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021146424A1 (en) * | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MX2022012678A (es) * | 2020-04-08 | 2023-01-11 | Remix Therapeutics Inc | Compuestos y metodos para modular el corte y empalme. |
| CN112010860B (zh) * | 2020-08-05 | 2023-03-10 | 南京纳丁菲医药科技有限公司 | 苄氧基吡唑并嘧啶化合物和药物组合物及其应用 |
| AU2021320860A1 (en) * | 2020-08-05 | 2023-02-23 | The General Hospital Corporation | Salt inducible kinase inhibitors |
| IL301768A (en) * | 2020-09-30 | 2023-05-01 | Fl2022 001 Inc | Hsd17b13 inhibitors and uses thereof |
| JP7805363B2 (ja) | 2020-11-02 | 2026-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体 |
| US20240158392A1 (en) * | 2021-02-01 | 2024-05-16 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| WO2022165530A1 (en) * | 2021-02-01 | 2022-08-04 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20230053049A (ko) * | 2021-10-13 | 2023-04-21 | 서울대학교산학협력단 | 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
| CN118119619A (zh) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| AR128279A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| AR128280A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Derivados de bencimidazol piridina |
| WO2023164236A1 (en) * | 2022-02-28 | 2023-08-31 | Agios Pharmaceuticals, Inc. | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations |
| WO2023164233A1 (en) * | 2022-02-28 | 2023-08-31 | Agios Pharmaceuticals, Inc. | (4-benzo[d]oxazol-2-yl)-6,7-dihydro-1h-imidazo[4,5-c]pyridine-5(4h)-yl)methanone derivatives as mutant pah stabilizers for the treatment of phenylketonuria |
| CN117843634A (zh) * | 2022-05-24 | 2024-04-09 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| EP4547662A1 (en) * | 2022-07-01 | 2025-05-07 | F. Hoffmann-La Roche AG | Imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives as sik modulators for the treatment of rheumatoid arthritis |
| US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| EP4642773A1 (en) * | 2022-12-27 | 2025-11-05 | F. Hoffmann-La Roche AG | New benzimidazole derivatives |
| TW202509021A (zh) | 2023-05-24 | 2025-03-01 | 日商田邊三菱製藥股份有限公司 | 鹽誘導之激酶抑制化合物以及包含其之醫藥組成物 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| CN121712757A (zh) * | 2023-07-19 | 2026-03-20 | 豪夫迈·罗氏有限公司 | 苯并咪唑作为sik活性调节剂 |
| WO2025017043A1 (en) | 2023-07-19 | 2025-01-23 | F. Hoffmann-La Roche Ag | New benzimidazole pyridine derivatives |
| TW202547512A (zh) * | 2024-05-01 | 2025-12-16 | 美商林伯士薩拉西亞公司 | Sik2調節劑及其用途 |
| WO2025231112A1 (en) * | 2024-05-01 | 2025-11-06 | Nimbus Salacia, Inc. | Sik2 modulators and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008279759A1 (en) * | 2007-07-20 | 2009-01-29 | Merck & Co., Inc. | Pyrazolo[1,5-a]pyrimidine derivatives |
| ES2375425T3 (es) | 2007-07-26 | 2012-02-29 | Novartis Ag | Compuestos org�?nicos. |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| AU2009279936A1 (en) * | 2008-08-05 | 2010-02-11 | Banyu Pharmaceutical Co., Ltd. | Therapeutic compounds |
| GB201204384D0 (en) * | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| EP3344039A4 (en) * | 2015-09-03 | 2019-08-28 | Arizona Board of Regents on behalf of the University of Arizona | LOW MOLECULAR DYRK1A INHIBITORS AND USES THEREOF |
| SG11202004925QA (en) * | 2017-12-02 | 2020-06-29 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| AU2021320860A1 (en) | 2020-08-05 | 2023-02-23 | The General Hospital Corporation | Salt inducible kinase inhibitors |
-
2018
- 2018-11-26 SG SG11202004925QA patent/SG11202004925QA/en unknown
- 2018-11-26 IL IL274938A patent/IL274938B2/en unknown
- 2018-11-26 HU HUE18811769A patent/HUE057581T2/hu unknown
- 2018-11-26 MX MX2020005423A patent/MX2020005423A/es unknown
- 2018-11-26 KR KR1020207019014A patent/KR102720958B1/ko active Active
- 2018-11-26 PH PH1/2020/550725A patent/PH12020550725B1/en unknown
- 2018-11-26 ES ES18811769T patent/ES2908283T3/es active Active
- 2018-11-26 BR BR112020010364-0A patent/BR112020010364A2/pt unknown
- 2018-11-26 PT PT188117691T patent/PT3717471T/pt unknown
- 2018-11-26 PL PL18811769T patent/PL3717471T3/pl unknown
- 2018-11-26 MY MYPI2020002758A patent/MY201849A/en unknown
- 2018-11-26 WO PCT/EP2018/082537 patent/WO2019105886A1/en not_active Ceased
- 2018-11-26 EP EP18811769.1A patent/EP3717471B1/en active Active
- 2018-11-26 DK DK18811769.1T patent/DK3717471T3/da active
- 2018-11-26 MA MA051200A patent/MA51200A/fr unknown
- 2018-11-26 AU AU2018374456A patent/AU2018374456B2/en active Active
- 2018-11-26 CN CN201880077841.9A patent/CN111433200B/zh active Active
- 2018-11-26 US US16/768,825 patent/US11339166B2/en active Active
- 2018-11-26 JP JP2020529717A patent/JP7326276B2/ja active Active
- 2018-11-26 CA CA3084090A patent/CA3084090A1/en active Pending
- 2018-11-30 TW TW107142872A patent/TW201930301A/zh unknown
-
2020
- 2020-06-30 CO CONC2020/0008066A patent/CO2020008066A2/es unknown
- 2020-07-01 ZA ZA2020/04025A patent/ZA202004025B/en unknown
-
2022
- 2022-03-02 CY CY20221100182T patent/CY1125044T1/el unknown
- 2022-04-13 US US17/719,653 patent/US12065443B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005423A (es) | Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. | |
| DOP2021000227A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades | |
| CO2021000159A2 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades | |
| DOP2017000139A (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
| CO2020005200A2 (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| DOP2017000013A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| IT201700085508A1 (it) | Metodo per la produzione di cannabinoidi da varietà di canapa industriale | |
| CO2018009876A2 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de fibrosis | |
| AR086042A1 (es) | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica | |
| ECSP15045801A (es) | Inhibidores de la phd de 6(5hidroxi1hpirazol1il)nicotinamida | |
| MX378299B (es) | Metodos para tratar infecciones por el virus de filoviridae. | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| MX392523B (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar | |
| AR089960A1 (es) | Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias | |
| BR112017005109A2 (pt) | produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário | |
| BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
| IL288298A (en) | Production of glass bodies from polymerizable solutions | |
| EP3383408A4 (en) | REGULATION OF CYTOKIN PRODUCTION | |
| CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
| MX2021010093A (es) | Derivados de pirazolopiridina como inhibidores serina/treonina cinasa que contiene el dominio per-arnt-sim (pask). | |
| IT201700074911A1 (it) | Procedimento per la produzione di olefine da alcoli | |
| PT4041186T (pt) | Composição farmacêutica anidra para tratamento de manutenção da psoríase | |
| CO2019010117A2 (es) | Proceso para la separación de isómeros ópticos de etilésteres racémicos del ácido 3-alquilpiperidin-carboxílico | |
| AR133956A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades |